Want to see AZTR full AI Analyst Report?
Top Page
Azitra Inc
(AZTR)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.12
▼(-6.15% Downside)
Action:Reiterated
Date:08/21/26
The score is primarily held down by weak financial performance (pre-revenue, ongoing losses, and significant cash burn/TTM cash-flow concerns). Technicals add pressure with a clear downtrend versus key moving averages and negative MACD. Corporate events provide a mild offset (listing compliance regained and strategy/funding initiatives), but not enough to overcome the fundamental and trend headwinds.
Positive Factors
Low Leverage and Improved Capitalization
Low debt and repaired capitalization give Azitra more financial flexibility than its loss profile alone suggests. This can support continued clinical and platform investment, although ongoing losses still limit the strength of the balance-sheet improvement.
Negative Factors
Pre-Revenue and Persistent Losses
Azitra has not established recurring commercial revenue and continues to absorb substantial annual losses. Without validated product sales, future value depends heavily on clinical progress, partnerships, or additional financing rather than an internally funded operating model.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage and Improved Capitalization
Low debt and repaired capitalization give Azitra more financial flexibility than its loss profile alone suggests. This can support continued clinical and platform investment, although ongoing losses still limit the strength of the balance-sheet improvement.
Read all positive factors
Azitra Inc (AZTR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.68M
Dividend YieldN/A
Average Volume (3M)169.78K
Price to Earnings (P/E)―
Beta (1Y)1.19
Revenue GrowthN/A
EPS Growth78.16%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.46
Shares Outstanding60,603,740
10 Day Avg. Volume152,326
30 Day Avg. Volume169,784
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.11
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.26
Revenue Forecast (FY)N/A
Azitra Inc Business Overview & Revenue Model
Company Description
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The ...
How the Company Makes Money
null...
Azitra Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
5
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 7.50K | 686.00K | 284.00K | 110.00K |
| Gross Profit | 0.00 | 0.00 | 7.50K | 686.00K | 284.00K | 110.00K |
| EBITDA | -5.22M | -10.49M | -8.50M | -10.67M | -10.02M | -8.79M |
| Net Income | -12.27M | -10.96M | -8.97M | -11.28M | -10.68M | -8.94M |
Balance Sheet | ||||||
| Total Assets | 8.92M | 5.03M | 7.36M | 5.12M | 7.17M | 10.20M |
| Cash, Cash Equivalents and Short-Term Investments | 6.73M | 2.07M | 4.55M | 1.80M | 3.49M | 8.04M |
| Total Debt | 410.05K | 422.08K | 555.51K | 885.95K | 7.73M | 992.02K |
| Total Liabilities | 1.58M | 1.22M | 1.66M | 2.20M | 43.43M | 35.97M |
| Stockholders Equity | 7.33M | 3.80M | 5.70M | 2.91M | -36.26M | -25.77M |
Cash Flow | ||||||
| Free Cash Flow | -5.83B | -11.41M | -10.56M | -7.68M | -8.69M | -8.72M |
| Operating Cash Flow | -5.77B | -11.22M | -10.18M | -7.36M | -8.35M | -8.07M |
| Investing Cash Flow | -279.62K | -182.91K | -379.25K | -318.26K | -336.76K | -652.27K |
| Financing Cash Flow | 17.07M | 8.92M | 13.32M | 5.98M | 4.13M | 992.86K |
Azitra Inc Technical Analysis
Negative
0.13
Price Trends
0.15
Negative
0.19
Negative
0.23
Negative
Market Momentum
>-0.01
Negative
43.24
Neutral
13.58
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTR, the sentiment is Negative. The current price of 0.13 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.15, and below the 200-day MA of 0.23, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.24 is Neutral, neither overbought nor oversold. The STOCH value of 13.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AZTR.
Azitra Inc Risk Analysis
Azitra Inc disclosed 47 risk factors in its most recent earnings report. Azitra Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Azitra Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $7.68M | -0.09 | -251.51% | ― | ― | 78.16% | |
| ― | $2.44M | -0.15 | -177.32% | ― | ― | 86.26% | |
60 Neutral | $5.24M | >-0.01 | -72.72% | ― | -34.06% | 79.61% | |
44 Neutral | $6.22M | -0.09 | -220.99% | ― | ― | 87.05% | |
33 Underperform | $2.63M | -0.07 | -105.46% | ― | -51.33% | 99.22% |
* Healthcare Sector Average
AZTR
Azitra Inc
0.13
-0.79
-85.70%
OGEN
Oragenics
0.53
-0.58
-52.27%
INM
InMed Pharmaceuticals
1.46
-0.82
-35.96%
ENVB
Enveric Biosciences
1.43
-13.21
-90.23%
SPRC
SciSparc Ltd.
6.70
-35.01
-83.95%
ONCO
Onconetix
0.65
-147.85
-99.56%
Azitra Inc Corporate Events
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Azitra Regains NYSE American Listing Compliance Status
Positive
Aug 21, 2026
Azitra, Inc., a clinical-stage biopharmaceutical group specializing in precision dermatology, cosmeceuticals and biotech applications, is developing key programs including ATR-COSF for cosmetic and skincare uses and ATR-04 for EGFR inhibitor-assoc...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Azitra Announces Strategic Shift Toward Cosmetics and Biotech Tools
Positive
Jun 17, 2026
Azitra Inc. detailed a strategic reorientation in a June 17, 2026 shareholder letter, following a March financing that raised $10.5 million with additional capital potential through warrant exercises. The company is shifting resources toward progr...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
Azitra Expands Authorized Shares Following Stockholder Approvals
Neutral
Jun 16, 2026
On June 15, 2026, Azitra, Inc. filed an amendment to its certificate of incorporation in Delaware to increase its authorized common stock from 200,000,000 to 750,000,000 shares, following stockholder approval at its reconvened 2026 annual meeting....
Shareholder Meetings
Azitra Adjourns 2026 Annual Meeting for Lack of Quorum
Negative
Jun 4, 2026
Azitra Inc., a clinical-stage biopharmaceutical company specializing in precision dermatology, is advancing two main programs: ATR-12 for Netherton syndrome, a rare and often severe genetic skin disorder, and ATR-04 for rashes associated with EGFR...
Shareholder Meetings
Azitra Adjusts 2026 Annual Shareholders Meeting Schedule
Neutral
May 27, 2026
On May 27, 2026, Azitra Inc. announced that it would open its 2026 annual shareholders’ meeting on June 4, 2026, solely to immediately adjourn it and reconvene on June 15, 2026, in a virtual format. The company cited a minor administrative d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.